Long-Term TRT Dosing: Standard Protocols, Microdosing, and Injection Techniques

Why Dosing Strategy Changes Over Time

Long-term TRT is not a set-and-forget prescription. The dose that stabilizes your testosterone at 9 months may produce supraphysiologic peaks or symptomatic troughs at 24 months as body composition, injection technique, and metabolic rate shift. A 2021 registry study of 656 hypogonadal men followed for a median of 11 years found that dose adjustments were made in roughly 38% of patients during the first 3 years of therapy, with the majority of changes occurring in the first 12 months of treatment. [1]

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend titrating the testosterone dose to achieve serum testosterone levels in the mid-normal range (400 to 700 ng/dL) with the goal of alleviating symptoms." [2] That titration process never fully stops. Body weight changes of 10 pounds or more, shifts in injection site rotation, and changes in subcutaneous fat depth all alter drug pharmacokinetics enough to require reassessment.

Two factors make long-term dosing different from short-term dosing. First, hematocrit tends to rise gradually over 6 to 18 months even when the dose stays constant, because erythropoiesis stimulation is cumulative. Second, testicular atrophy and suppression of the hypothalamic-pituitary-gonadal axis deepen with time, making dose reductions harder to manage symptomatically. Planning for both phenomena from the start of therapy prevents reactive, crisis-driven dose changes later.

Standard TRT Protocol: Doses and Frequencies

The most prescribed long-term protocol in the United States is testosterone cypionate 100 to 200 mg intramuscularly (IM) once per week, or split into two 50 to 100 mg injections twice per week. [2] Testosterone enanthate follows an identical dosing framework given its nearly identical half-life of approximately 8 days versus cypionate's 8 to 12 days.

Weekly injection of 200 mg cypionate produces a peak serum testosterone of roughly 1,200, 1 to 500 ng/dL at 48 to 72 hours and a trough near 300 to 400 ng/dL just before the next injection. That 1,000+ ng/dL swing causes symptoms in a meaningful subset of patients: energy and libido spike mid-week, then drop before the next dose. Splitting the same 200 mg into two 100 mg twice-weekly doses reduces the peak-to-trough delta to approximately 300 to 400 ng/dL, keeping most men in the 500 to 900 ng/dL range throughout the week. [3]

A concrete clinical trial example: in the Testosterone Trials (TTrials, N=788 men aged 65 and older), testosterone gel titrated to achieve levels of 500, 1 to 000 ng/dL produced significant improvements in sexual function and walking distance vs. placebo at 12 months. [4] While gel was the delivery vehicle in TTrials, the target range informs injectable dosing targets as well, and most prescribers translate that 500, 1 to 000 ng/dL window directly to injectable protocols.

For men who show hematocrit elevation above 50% or persistently high estradiol on twice-weekly injections, reducing to the same total weekly dose divided into three or even four smaller injections flattens the curve further without reducing total androgen exposure.

Daily Microdosing: Who Benefits and How It Works

Daily microdosing means injecting 10 to 20 mg of testosterone cypionate or enanthate subcutaneously (SQ) every day, typically using a 27, 29 gauge insulin syringe. The total weekly dose (70 to 140 mg) sits within the same therapeutic range as standard protocols, but the near-constant input mimics endogenous diurnal testosterone secretion far more closely than any multi-day injection schedule.

The clinical rationale is pharmacokinetic. Testosterone cypionate has a half-life of 8 to 12 days, so daily 14 mg doses reach steady state within 3 to 4 weeks and then maintain serum testosterone within a 100 to 200 ng/dL window around the target all day, every day. There are no mid-week peaks that spike estradiol, no pre-injection troughs that cause fatigue, and hematocrit tends to rise less aggressively because there are no supraphysiologic peaks driving burst erythropoiesis. [5]

The following decision framework guides which patients are best suited for daily microdosing versus standard twice-weekly injections:

Daily microdosing is preferred when:

• Hematocrit exceeds 50% on twice-weekly dosing at therapeutic totals
• Estradiol climbs above 50 pg/mL despite no aromatase inhibitor
• The patient reports mid-cycle mood swings, energy crashes, or libido variability
• Injection anxiety is low and the patient values consistency over fewer injections

Twice-weekly standard dosing is preferred when:

• The patient has a strong preference for fewer injection events
• Compliance with daily administration is a concern
• Therapeutic response is stable and labs are within target on twice-weekly doses

One practical point: insulin syringes hold a maximum of 1 mL, and most testosterone cypionate is supplied at 200 mg/mL. A 14 mg daily dose is only 0.07 mL, which is difficult to measure accurately in a standard 1 mL syringe. Prescribing 100 mg/mL concentration instead of 200 mg/mL makes the draw volume 0.14 mL, more than twice as easy to measure precisely. Confirm the concentration of your vial before calculating daily draw volumes.

Intramuscular vs. Subcutaneous Injection: Clinical Comparison

For at least four decades, IM injection into the gluteus maximus was the textbook standard for testosterone delivery. The assumption was that a deep oil depot in dense muscle produced more predictable absorption than subcutaneous fat. That assumption has been revised. A 2021 pharmacokinetic study (N=32) comparing IM and SQ testosterone cypionate injections of identical doses found no statistically significant difference in Cmax, Tmax, or AUC between the two routes, with both routes achieving similar therapeutic levels within the first 48 to 72 hours post-injection. [6]

SQ administration carries several practical advantages for long-term use. Needle length drops from 1, 1.5 inches (IM) to 5/8 inch or shorter (SQ), reducing injection discomfort significantly. Injection site options expand to include abdominal fat and lateral thigh fat in addition to the deltoid and glute fat, distributing site wear over more locations. Post-injection pain and nodule formation at the injection site occur in roughly 12% of SQ patients in observational data, but most cases resolve within 48 hours and are managed by rotating injection sites more frequently. [6]

IM injection remains the preferred route in specific circumstances: very lean patients with minimal subcutaneous fat (<5 mm skinfold at intended site), patients on anticoagulants where SQ bruising is problematic, and patients who prefer the established clinical tradition of IM delivery.

Key pharmacokinetic comparison:

| Parameter | IM (Gluteus, 1.5 in, 23G) | SQ (Abdomen/Thigh, 5/8 in, 27G) | |---|---|---| | Onset to Cmax | 24 to 72 hours | 24 to 72 hours | | Cmax (200 mg dose) | ~1,200, 1 to 500 ng/dL | ~1,100, 1 to 400 ng/dL | | Trough (Day 7) | ~300 to 400 ng/dL | ~300 to 450 ng/dL | | Patient comfort | Moderate | Higher | | Preferred needle gauge | 23, 25G | 27, 29G |

Source: Pharmacokinetic data from Olson et al. 2021 and Endocrine Society 2018 guidelines. [2, 6]

Injection Technique: Step-by-Step for Long-Term Safety

Correct technique reduces the two most common long-term complications of self-injection: site induration (scar tissue buildup) and intravascular injection. Both become more likely as the same small number of sites are used repeatedly over months and years.

Supplies needed:

• Testosterone vial (cypionate or enanthate, physician-prescribed concentration)
• Drawing needle: 18G, 1.5 in (to pull oil from vial quickly)
• Injection needle: 23, 25G, 1 to 1.5 in for IM; 27, 29G, 5/8 in for SQ
• 1 to 3 mL luer-lock syringe
• Alcohol swabs (two per injection)
• Sterile gauze or cotton ball

Step-by-step protocol:

1. Wash hands for 20 seconds with soap and water.
2. Swab the vial stopper with an alcohol swab and allow it to air-dry for 10 seconds.
3. Attach the 18G drawing needle to the syringe and draw back a volume of air equal to your dose.
4. Insert the drawing needle into the vial, invert, and inject the air. Draw the oil slowly to avoid bubbles. Pull slightly past your dose volume, then gently tap and push out any air bubbles back to the exact dose line.
5. Swap to your injection needle. Do not recap the drawing needle with the injection needle in hand.
6. Swab the injection site and allow 10 seconds to dry. Wet alcohol stings and may cause localized reaction.
7. For IM: stretch the skin taut and insert at 90 degrees with a smooth dart motion. Aspirate for 5, 10 seconds. If blood appears in the syringe, withdraw, discard, and start fresh. Inject slowly over 15, 30 seconds.
8. For SQ: pinch a fold of fat, insert at 45 degrees, release the pinch, then inject over 10, 15 seconds.
9. Withdraw smoothly. Apply light pressure with gauze for 30 seconds. Do not rub.
10. Rotate to a new site at every injection. Keep a written or app-based log.

Long-term site rotation schedule (IM example):

Week 1 Monday: Right gluteus upper outer quadrant. Week 1 Thursday: Left gluteus upper outer quadrant. Week 2 Monday: Right vastus lateralis. Week 2 Thursday: Left vastus lateralis. Then repeat. This four-site rotation gives each site 14 days of rest on a twice-weekly schedule, reducing the cumulative scar tissue load that builds up over months and years of injections.

Nodule formation at SQ sites can be reduced by warming the oil to body temperature (hold the capped syringe in your fist for 2 minutes before injection) and injecting even more slowly. Cold oil in subcutaneous fat is the primary driver of post-injection lumps in daily microdosers.

Long-Term Safety Monitoring: The Lab Schedule That Matters

Long-term TRT safety depends far more on consistent monitoring than on any single dosing decision. The Endocrine Society guideline recommends checking total testosterone, hematocrit, and PSA at 3 months after any dose change, then every 6 months once stable. [2] The American Urological Association's 2024 testosterone deficiency guideline reinforces this, adding that digital rectal exam (DRE) is optional in men with PSA <4.0 ng/mL and no urinary symptoms. [7]

Key lab thresholds and actions:

• Total testosterone trough: Target 400 to 700 ng/dL at trough (just before next injection). If >900 ng/dL at trough, reduce weekly dose by 10 to 20%.
• Hematocrit: Hold therapy and refer to hematology if hematocrit >54%. Reduce dose if hematocrit reaches 52 to 54% on two consecutive draws. [2]
• Estradiol (sensitive LC-MS/MS assay): Target 20, 40 pg/mL. Levels >50 pg/mL with symptoms (gynecomastia, water retention, libido changes) may warrant low-dose anastrozole 0.25 to 0.5 mg twice weekly, though routine aromatase inhibitor use without symptoms is not recommended.
• PSA: A confirmed rise of >1.4 ng/mL above baseline within any 12-month period, or a PSA >4.0 ng/mL, warrants urology referral before continuing TRT. [2]
• LH/FSH: Suppressed to near-zero on TRT. This finding alone does not require action, but confirms HPG axis suppression.
• SHBG: Measure annually. Low SHBG (<20 nmol/L) means more free testosterone per total dose; these patients may need lower total doses to stay within trough targets.

A 2014 meta-analysis of 19 randomized controlled trials (N=1,084 men) found no statistically significant increase in major adverse cardiovascular events (MACE) in men treated with testosterone vs. placebo over follow-up periods of 6 to 36 months, though the authors noted that study populations were heterogeneous and long-term cardiovascular data were insufficient at that time. [8] The TRAVERSE trial (N=5,204, published 2023) subsequently provided the most strong long-term cardiovascular data to date, finding non-inferiority of testosterone versus placebo for MACE at a median follow-up of 33 months in men aged 45, 80 with low testosterone and elevated cardiovascular risk. [9]

The TRAVERSE authors note: "Testosterone replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiovascular events." [9] This finding has been incorporated into updated prescribing guidance and supports continued long-term use in appropriately monitored patients.

Fertility Preservation During Long-Term TRT

Exogenous testosterone suppresses LH and FSH through negative feedback on the hypothalamus and pituitary, reducing intratesticular testosterone production and sperm output to near-zero within 3 to 6 months in most men. This effect is dose-dependent and largely reversible, but recovery time after years of therapy may extend to 12 to 24 months in some patients. [10]

Men who may want biological children in the future require co-administration of human chorionic gonadotropin (hCG), which mimics LH and maintains intratesticular testosterone production. The standard protocol is hCG 500 IU subcutaneously every other day alongside testosterone therapy. A 2015 study by Coviello et al. demonstrated that hCG 500 IU every other day maintained intratesticular testosterone concentrations above the threshold required for spermatogenesis in men on exogenous testosterone. [10] Sperm banking before starting TRT remains the most reliable fertility protection strategy for men with definite future fertility plans.

Dose Adjustments at Key Life Transitions

Long-term TRT crosses multiple life phases. Three transitions warrant proactive dose review:

Weight gain of >15 lbs: Adipose tissue increases aromatase activity, converting more testosterone to estradiol. Total testosterone may appear adequate on labs, but free testosterone drops as SHBG changes. A modest dose increase of 10 to 15% or addition of an aromatase inhibitor may be appropriate based on symptoms and estradiol levels.

Weight loss of >15 lbs (including post-bariatric surgery): Reduced aromatization means more testosterone stays as testosterone. Hematocrit climbs faster. Trough testosterone may exceed target range at the same weekly dose. Plan a lab check 6 weeks after significant weight loss.

Age 65 and older: The TRAVERSE trial enrolled men up to age 80, supporting continued use in older patients. Bone density monitoring via DEXA scan every 1 to 2 years becomes relevant because both hypogonadism and the therapy itself affect bone metabolism, and a baseline DEXA at the start of therapy provides the most useful long-term comparison.

Compounded vs. FDA-Approved Formulations

Most long-term TRT in the United States uses either FDA-approved testosterone cypionate (Depo-Testosterone, Pfizer) or compounded testosterone cypionate from a 503B outsourcing facility. The 503A and 503B compounding pathways are regulated differently: 503B facilities face stricter FDA oversight, sterility testing, and potency verification than 503A pharmacies. [11]

Potency variation in compounded testosterone has been documented, with some 503A pharmacy samples testing outside the labeled concentration by more than 10% in independent analyses. For long-term dosing precision, requesting that your pharmacy source from a 503B-registered outsourcing facility or prescribing the FDA-approved branded or generic cypionate vials eliminates concentration uncertainty.

The FDA-approved testosterone undecanoate (Aveed, intramuscular) and testosterone pellets (Testopel) represent alternative long-term delivery methods. Aveed requires a 3 mL deep IM injection at 0, 4, and then every 10 weeks, with administration only in a healthcare setting due to a risk of pulmonary oil microembolism. Testopel pellets are implanted subcutaneously every 3 to 6 months under local anesthesia, with dose titration being less precise than injectable formats.